Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous tetravalent dendritic cell vaccine MIDRIX4-LUNG

A therapeutic cancer vaccine composed of autologous, dendritic cells (DCs) that have been loaded with a proprietary selection of four antigens that covers more than ninety percent of all non-small cell lung cancer (NSCLC) patients, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous tetravalent dendritic cell vaccine MIDRIX4-LUNG may induce and stimulate both T-helper and antigen-specific cytotoxic T-lymphocyte (CTL) responses, leading to tumor cell lysis in patients with NSCLC.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous DC vaccine MIDRIX4-LUNG
autologous tetravalent DC vaccine MIDRIX4-LUNG
tetravalent autologous dendritic cell vaccine MIDRIX4-LUNG
Code name:MIDRIX4-LUNG
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search